News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

Upcoming Events Jefferies London Healthcare Conference NOV 16 - NOV 18, 2021 PiperSandler 33rd Annual Healthcare Conference NOV 30 - DEC 2, 2021

Unterhaltung  Tulio de Oliveira @Tuliodna So excited that we are launching the largest Genomics Facility on the African continent at CERI. Thanks, @DrPatSoonShiong @RickABright @fdesouza @RockefellerFdn @illumina @PresidencyZA to believe that Africa can lead in genomics response to epidemics . https://mobile.twitter.com/Tuliodna/status/1441115595731132419?s=19

ImmunityBio, Inc. hat retweetet Cyril Ramaphosa #VoteANC 9 Std. "Three, Dr. Soon- Shiong has identified excellent institutions with the capacity and capabilities to spread their technologies beyond our borders." https://mobile.twitter.com/immunitybio?lang=de

President Cyril Ramaphosa attends the launch announcement by Dr Soon-Shiong of NantAfrica COVID-19 https://www.youtube.com/watch?v=7LM6_OciAx4

 Presidency | South Africa  @PresidencyZA [WATCH]: President @CyrilRamaphosa is the guest of honour at an announcement of an initiative ambitious initiative to build capacity for advanced health care in Africa by Dr Patrick Soon-Shiong, founder of the multinational conglomerate, NantWorks LLC.

NantAfrica to launch ambitious COVID-19, cancer vaccine initiative https://www.sanews.gov.za/south-africa/nantafrica-launch-ambitious-covid-19-cancer-vaccine-initiative

Immunity Bio on linkedin: "Some Vaccines Last a Lifetime. Here's Why Covid-19 Shots Don't." Excellent article by Jo Craven McGinty in today's The Wall Street Journal on why some vaccines generate more immune memory than others. Note that 17 years after recovery from SARS-CoV-1 infection, patients still had reactive T-cells to the virus. B cells forget T cells remember. Click here to listen or read the full story: https://on.wsj.com/3lNf3Ny #IBRX #ImmunityBio #COVID19 #Vaccine

Adobe and Immunity Bio Blockchain Patent Applications https://www.managingrights.com/2021/05/adobe-and-immunity-bio-blockchain-patent-applications.html

Das zweite Video von oben ist wirklich sehr interessant. Hier geht er noch einmal mehr ins Detail, erklärt seine Motivation und Hindernisse und erklärt für Leihen die Funktionsweise seines T-Zellen Ansatz. Interessant war auch die Vergrößerung einer T-Zelle wie sie geziehlt Krebszellen vernichtet, oder, dass Immunity Bio ursprünglich Mitglied des Warp Speed Programms sein sollte, (zur Beschleunigung der US Impfkampagne) die Mitgliederzahl aber von 8 auf 6 verkürzt wurde und Immunitybio rausfiel.

#COVID19SA Early data from a Phase 1 clinical trial of ImmunityBio’s hAd5 T-cell COVID-19 vaccine candidate being evaluated in Cape Town has shown the jab is safe. @BrandtKev- KB https://mobile.twitter.com/ewnreporter/status/1439791776110419969?s=20

Dr Pat provides an update of his plans/progress in South Africa… https://youtu.be/aXhoHOcVK4Q

Aus einem Twitter Post könnte hervorgehen, dass IBRX mit Amyris zusammen an einem Covid Impfstoff arbeitet. https://mobile.twitter.com/ibioindex/status/1429382699815481350

"Check out this job at ImmunityBio, Inc.: Associate Director, Microbiology & Sterility Control $IBRX $XBI Gearing up for commercialization. Apparently they are sure of some approvals!" https://www.linkedin.com/jobs/view/2718002649

5 reasons why the FDA advisers did not recommend covid 19 boosters for everyone "Immunologists point out that long-lasting protection comes from immune cells called B-cells and T-cells, and Pfizer only presented data on antibody response." https://edition.cnn.com/2021/09/17/health/fda-advisers-booster-five-things/index.html

ImmunityBio, Inc. @ImmunityBio vor 16 Std. Non-human primate study shows protection against SARS-CoV-2 challenge in lung and nasal passages. Special thanks to NIH/NIAID and ASPR/BARDA for their support on this important study. #COVID19 #Vaccine

In comparison to other FDA-approved treatments for this patient population, N-803 plus BCG significantly improved outcomes. Previous data with pembrolizumab (Keytruda) showed that the agent induced at CR rate of 41% at any time, and a median duration of CR of 16.2 months at 24.1 months follow-up. Similarly, valrubicin elicited an 18% CR rate, and a median duration of CR of less than 6 months. Moreover, the cystectomy-free rate for the two drugs was 63% and 76%, respectively. Reference Chamie K, Chang S, Gonzalgo M, et al. Phase 2/3 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ (CIS) patients (cohort A). Presented at: 2021 American Urological Association Annual Meeting; September 10-13, 2021; virtual. Abstract PD09-05. https://www.onclive.com/view/n-803-bcg-combo-shows-promising-responses-tolerability-in-bcg-unresponsive-bladder-cancer